Trials / Completed
CompletedNCT05650164
Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)
A Multicenter, NI, Retrospective, Observational Study Evaluating Real-World Treatment Outcomes in Japanese Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Avelumab Plus Axitinib as First-line Therapy: J-DART2
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 171 (actual)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | avelumab | as provided in real world practice |
| DRUG | axitinib | as provided in real world practice |
Timeline
- Start date
- 2023-01-25
- Primary completion
- 2023-10-13
- Completion
- 2023-10-13
- First posted
- 2022-12-14
- Last updated
- 2025-03-28
- Results posted
- 2025-03-28
Locations
19 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT05650164. Inclusion in this directory is not an endorsement.